Substance P vs Noopept
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Noopept
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.
Full details →Side-by-Side Comparison
| Aspect | Substance P | Noopept |
|---|---|---|
| Mechanism | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. | Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms. |
| Typical Dosage | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. | Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau. |
| Administration | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. | Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food. |
| Side Effects | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. | Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use. |
| Best For |
What They Have in Common
Both Substance P and Noopept are commonly used for: